vimarsana.com
Home
Live Updates
Survey Epidemiology - Breaking News
Pages:
Latest Breaking News On - Survey epidemiology - Page 1 : vimarsana.com
Real-World Survival Benefit With CDK4/6 Inhibitors in MBC
Registry data confirm an overall survival benefit when a CDK4/6 inhibitor is added to endocrine therapy in HR-positive metastatic breast cancer.
Boston
Massachusetts
United-states
Dana-farber-cancer-institute
Erica-mayer
Ravi-goyal
Dario-trapani
Drug-administration
College-of-pharmacy
University-of-houston
Survey-epidemiology
End-results
vimarsana © 2020. All Rights Reserved.